Human IFN-gamma R2 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF773
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
CyTOF-ready, Flow Cytometry, Neutralization, Western Blot
Cited:
Flow Cytometry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human IFN-gamma R2
Ala22-Gln247
Accession # P38484
Ala22-Gln247
Accession # P38484
Specificity
Detects human IFN-gamma R2 in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IFN-gamma R2 Antibody
Detection of IFN‑ gamma R2 in human blood‑derived granulocytes
Blood-derived granulocytes were stained with Goat Anti-Human IFN-gamma R2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF773, filled histogram) or control antibody (Catalog # AB-108-C, open histogram), followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108).IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ gamma R2 Antibody.
Recombinant Human IFN-gamma (Catalog # 285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (2 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IFN-gamma R2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF773). The ND50 is typically 0.5-2.5 µg/mL.Detection of Human IFN-gamma R2 by Western Blot
B3GNT2 disrupts ligand–receptor interactions between tumor and T cells.a Cell survival against T cell cytotoxicity (top) and T cell IFN gamma secretion (bottom) in A375 cells overexpressing B3GNT2 or GFP that have been treated with different concentrations of kifunensine. Kifunensine was used to pretreat A375 cells and was present during co-culture with T cells at E:T ratio of 3. Kifunensine-treated cells that were co-cultured with ESO T cells were compared to kifunensine-treated cells cultured in parallel without T cells to determine percent survival. N = 6. Two-tailed t tests were performed. b Tomato lectin IP of A375 cells overexpressing GFP or B3GNT2 followed by western blot for different B3GNT2 target proteins. 2% of the input and no lectin IP controls are shown. Data are representative of two independent experiments. c Western blots of A375 cells overexpressing B3GNT2 or GFP that were treated with kifunensine (KIF) or benzyl-2-acetamido-2-deoxy-alpha -D-galactopyranoside (BAG) to remove N- or O-glycosylation respectively. Data are representative of two independent experiments. d Histograms (top) and corresponding median fluorescence intensity (MFI; bottom) showing binding of recombinant T cell proteins to A375 cells measured by flow cytometry. A375 cells were overexpressing GFP or B3GNT2 and treated with KIF or BAG. N = 3. Two-tailed t tests were performed. e Schematic showing the tumor cell surface ligands and receptors modified by B3GNT2 to disrupt interactions with T cells that mediate cytotoxicity. All values are mean ± s.e.m. ns not significant. Source data are provided in Source Data 4. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35338135), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human IFN-gamma R2 Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
2.5 µg/106 cells
Sample: Human blood-derived granulocytes
Sample: Human blood-derived granulocytes
Western Blot
0.1 µg/mL
Sample: Recombinant Human IFN-gamma R2
Sample: Recombinant Human IFN-gamma R2
Neutralization
Measured by its ability to neutralize IFN‑ gamma R2-mediated inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line [Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129]. The Neutralization Dose (ND50) is typically 0.5-2.5 µg/mL in the presence of 2 ng/mL Recombinant Human IFN‑ gamma.
Reviewed Applications
Read 1 review rated 4 using AF773 in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-gamma R2
Interferon gamma Receptor 2 (IFN-gamma R2) is a type II transmembrane protein that associates with IFN-gamma R1 to form a high affinity receptor complex for IFN-gamma. IFN-gamma R2 is required for signal transduction but does not bind IFN-gamma by itself.
Long Name
Interferon gamma Receptor 2
Alternate Names
AF-1, IFN-gR2, IFNgammaR2, IFNGR2, IFNGT1
Gene Symbol
IFNGR2
UniProt
Additional IFN-gamma R2 Products
Product Documents for Human IFN-gamma R2 Antibody
Product Specific Notices for Human IFN-gamma R2 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...